First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
We present two cases of von Hippel–Lindau (VHL) disease-associated hemangioblastomas in the CNS treated with the newly approved HIF-2α inhibitor, belzutifan. The first case is a 31-year-old female with confirmed pathogenic germline VHL mutation who presented with multiple hemangioblastomas. The pati...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis Group
2022-09-01
|
| Cyfres: | CNS Oncology |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0008 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|